The Form 4 filing, an SEC report of insider stock trades, was filed on Oct. 30, 2026. Both sales took place that day.
The transaction information notes a Rule 10b5-1 trading-plan reference. Such plans set trading instructions in advance. The details do not confirm whether the reference covers both sales.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-30 |
| Date of Latest Transaction | 2026-10-30 |
| Buy/Sell | sell |
| Transaction Count | 2 |
| Shares Transacted | 57,478 |
| Price | $44.09 |
| Total Transaction Value | $2,534,113.06 |
| Insider | |
| Ticker Symbol | BROS |
| Company | Dutch Bros Inc. |
| Insider Name | Boersma Travis |
| Insider Title | Executive Chairman of Board |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 2,198,060 |
| Position Size Change | 2.55% |
| Filing | |
| Filing Date | 2026-10-30 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of Dutch Bros (BROS) shares by Travis Boersma. The reported transaction code is S, which means a sale. The record covers two transactions in one filing.
What was the average price of the transaction?
The average price was $44.0884 per share, or $44.09 rounded to cents. This average covers the two reported sales. Separate prices for each sale are not available.
How did this transaction affect the insider's holdings?
Travis Boersma sold 57,478 shares and reported owning 2,198,060 shares afterward. The sales represented 2.55% of the shares he owned before the sales.
What's the total transaction value?
The two sales had a total value of $2,534,113.0552. Rounded to cents, the total was $2,534,113.06.
Are there any special circumstances around this transaction?
The Rule 10b5-1 plan reference is the special circumstance identified here. No footnote text is available to confirm which sales it covers. The plan's adoption date, schedule, and other terms are unknown. A plan reference alone does not show whether the plan met all legal requirements.
For research purposes only; not investment advice.